J
Justin Guinney
Researcher at Sage Bionetworks
Publications - 129
Citations - 21754
Justin Guinney is an academic researcher from Sage Bionetworks. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 32, co-authored 97 publications receiving 12819 citations. Previous affiliations of Justin Guinney include Duke University & University of Washington.
Papers
More filters
Journal ArticleDOI
Impact of centralization on aCGH-based genomic profiles for precision medicine in oncology
Frédéric Commo,Frédéric Commo,Charles Ferté,Charles Ferté,J-C. Soria,Stephen H. Friend,Fabrice Andre,Justin Guinney +7 more
TL;DR: The centralization method substantially affects the call detection of CGH profiles and may thus impact precision medicine approaches.
Journal ArticleDOI
Multi-targeting Drug Community Challenge
Avner Schlessinger,Ruben Abagyan,Heather A. Carlson,Kristen K. Dang,Justin Guinney,Ross L. Cagan +5 more
TL;DR: Polypharmacology can be effective in a broad palette of diseases including central nervous system disorders, diabetes, and cancer and its strength lies in the ability to “shift networks” into configurations that reduce disease while minimizing whole body toxicity.
Journal ArticleDOI
A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.
Fatemeh Seyednasrollah,Devin C. Koestler,Tao Wang,Stephen R. Piccolo,Roberto Vega,Russell Greiner,Christiane Fuchs,Eyal Gofer,Luke Kumar,Russell D. Wolfinger,Kimberly Kanigel Winner,Chris Bare,Elias Chaibub Neto,Thomas Yu,Liji Shen,Kald Abdallah,Thea Norman,Gustavo Stolovitzky,Howard R. Soule,Christopher Sweeney,Charles J. Ryan,Howard I. Scher,Oliver Sartor,Laura L. Elo,Fang Liz Zhou,Justin Guinney,James C. Costello +26 more
TL;DR: The results demonstrate that routinely collected clinical features can be used to identify patients with mCRPC who are likely to discontinue treatment because of adverse events and establishes a robust benchmark with implications for clinical trial design.
Journal ArticleDOI
A community challenge to evaluate RNA-seq, fusion detection, and isoform quantification methods for cancer discovery.
Allison L. Creason,David Haan,Kristen K. Dang,Kami E. Chiotti,Matthew Inkman,Andrew Lamb,Thomas Yu,Yin Hu,Thea Norman,Alex Buchanan,Marijke J. van Baren,Ryan Spangler,M. Rick Rollins,Paul T. Spellman,Dmitri V. Rozanov,Jin Zhang,Christopher G. Maher,Cristian Caloian,John D. Watson,Sebastian Uhrig,Brian J. Haas,Miten Jain,Mark Akeson,Mehmet Eren Ahsen,Hongjiu Zhang,Yifan Wang,Yuanfang Guan,Cu Nguyen,Christopher Sugai,Alokkumar Jha,Jing Woei Li,Alexander Dobin,Gustavo Stolovitzky,Gustavo Stolovitzky,Justin Guinney,Paul C. Boutros,Paul C. Boutros,Paul C. Boutros,Joshua M. Stuart,Kyle Ellrott +39 more
TL;DR: The ICGC-TCGA DREAM Somatic Mutation Calling in RNA (SMC-RNA) challenge as discussed by the authors was a crowd-sourced effort to benchmark methods for RNA isoform quantification and fusion detection from bulk cancer RNA sequencing (RNAseq) data.
Journal ArticleDOI
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
Long-Sheng Chang,Janet L. Oblinger,Abbi Smith,Marc Ferrer,Steven P. Angus,Steven P. Angus,Eric T. Hawley,Alejandra M. Petrilli,Roberta L. Beauchamp,Lars Björn Riecken,Serkan Erdin,Ming Poi,Jie Huang,Waylan K. Bessler,Xiaohu Zhang,Rajarshi Guha,Craig J. Thomas,Sarah S. Burns,Thomas S. K. Gilbert,Li Jiang,Xiaohong Li,Qingbo Lu,Jin Yuan,Yongzheng He,Shelley Dixon,Andrea R. Masters,David R. Jones,Charles W. Yates,Stephen J. Haggarty,Salvatore La Rosa,D. Bradley Welling,Anat Stemmer-Rachamimov,Scott R. Plotkin,James F. Gusella,Justin Guinney,Helen Morrison,Vijaya Ramesh,Cristina Fernandez-Valle,Gary L. Johnson,Jaishri O. Blakeley,D. Wade Clapp +40 more
TL;DR: In this article, a combination of high throughput screens, preclinical in vivo modeling, and evaluation of the kinome en masse, identified actionable drug targets and efficacious experimental therapeutics for the treatment of NF2 related schwannomas and meningiomas.